RFCA
PFE icon

R&F Capital Advisors’s Pfizer PFE Stock Holding History

R&F Capital Advisors’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$423K Sell
13,018
-28,836
-69% -$909K 0.11% 299
2016
Q4 		$1.29M Buy
+41,854
New +$1.28M 0.46% 49

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

R&F Capital Advisors's PFE Position: Q1 2017 in Review

R&F Capital Advisors reduced its Pfizer (PFE) stake by 69% in Q1 2017, selling an estimated $909K and leaving 13,018 shares worth $423K. The position accounts for 0.11% of the portfolio, ranked #299.

R&F Capital Advisors first reported a position in PFE in Q4 2016 and has held it in 2 quarters since. The position peaked at $1.29M in Q4 2016. 2,075 funds tracked by Wall St. Rank hold PFE as of Q1 2017.

  • R&F Capital Advisors held 13,018 shares of Pfizer worth $423K as of Q1 2017.
  • R&F Capital Advisors sold 28,836 Pfizer shares in Q1 2017, an estimated $909K.
  • Pfizer made up 0.11% of R&F Capital Advisors's portfolio in Q1 2017, its #299 holding.
  • R&F Capital Advisors first reported a position in Pfizer in Q4 2016 and has held it in 2 quarters since.
  • R&F Capital Advisors's Pfizer position peaked at $1.29M in Q4 2016.
  • 2,075 funds tracked by Wall St. Rank held Pfizer as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.